107 related articles for article (PubMed ID: 31498559)
21. Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells.
Lee W; Song G; Bae H
Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 35892941
[TBL] [Abstract][Full Text] [Related]
22. Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Study.
Innominato P; Komarzynski S; Karaboué A; Ulusakarya A; Bouchahda M; Haydar M; Bossevot-Desmaris R; Mocquery M; Plessis V; Lévi F
JCO Clin Cancer Inform; 2018 Dec; 2():1-15. PubMed ID: 30652550
[TBL] [Abstract][Full Text] [Related]
23. UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.
Abe S; Kubota T; Otani Y; Furukawa T; Watanabe M; Kumai K; Kitajima M
Jpn J Cancer Res; 2000 Nov; 91(11):1192-8. PubMed ID: 11092986
[TBL] [Abstract][Full Text] [Related]
24. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
25. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer.
Byrne JD; Jajja MRN; O'Neill AT; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Cancer Chemother Pharmacol; 2018 Jun; 81(6):991-998. PubMed ID: 29603014
[TBL] [Abstract][Full Text] [Related]
26. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
27. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Lang M; Wang X; Wang H; Dong J; Lan C; Hao J; Huang C; Li X; Yu M; Yang Y; Yang S; Ren H
Cancer Lett; 2016 Aug; 378(2):87-96. PubMed ID: 27212442
[TBL] [Abstract][Full Text] [Related]
28. KAI1 inhibits lymphangiogenesis and lymphatic metastasis of pancreatic cancer in vivo.
Liu X; Guo XZ; Li HY; Chen J; Ren LN; Wu CY
Hepatobiliary Pancreat Dis Int; 2014 Feb; 13(1):87-92. PubMed ID: 24463085
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
[TBL] [Abstract][Full Text] [Related]
30. Biologic effect of neurogenesis in pancreatic cancer.
He D; Manzoni A; Florentin D; Fisher W; Ding Y; Lee M; Ayala G
Hum Pathol; 2016 Jun; 52():182-9. PubMed ID: 26980040
[TBL] [Abstract][Full Text] [Related]
31. Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis.
Bozkurt Duman B; Çil T
J Oncol Pharm Pract; 2020 Oct; 26(7):1738-1742. PubMed ID: 32070199
[TBL] [Abstract][Full Text] [Related]
32. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
33. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Bueno-Silva B; de Alencar SM; Lombardi P; Mao W; Montalto G; Cervello M; Rakus D; Gizak A; Lin HL; Libra M; Akula SM; McCubrey JA
Adv Biol Regul; 2019 May; 72():22-40. PubMed ID: 30898612
[TBL] [Abstract][Full Text] [Related]
34. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
35. MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Fu X; Tang N; Xie WQ; Mao L; Qiu YD
Chin J Nat Med; 2020 Mar; 18(3):178-185. PubMed ID: 32245587
[TBL] [Abstract][Full Text] [Related]
36. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin.
Michl P; Buchholz M; Rolke M; Kunsch S; Löhr M; McClane B; Tsukita S; Leder G; Adler G; Gress TM
Gastroenterology; 2001 Sep; 121(3):678-84. PubMed ID: 11522752
[TBL] [Abstract][Full Text] [Related]
37. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
38. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions.
Neesse A; Hahnenkamp A; Griesmann H; Buchholz M; Hahn SA; Maghnouj A; Fendrich V; Ring J; Sipos B; Tuveson DA; Bremer C; Gress TM; Michl P
Gut; 2013 Jul; 62(7):1034-43. PubMed ID: 22677720
[TBL] [Abstract][Full Text] [Related]
39. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.
Ahmad G; Mackenzie GG; Egan J; Amiji MM
Mol Cancer Ther; 2019 Nov; 18(11):1961-1972. PubMed ID: 31439714
[TBL] [Abstract][Full Text] [Related]
40. Targeting claudin-4 in human pancreatic cancer.
Kojima T; Kyuno D; Sawada N
Expert Opin Ther Targets; 2012 Sep; 16(9):881-7. PubMed ID: 22800288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
